×
About 30,190 results

ALLMedicine™ Progesterone Center

Research & Reviews  9,571 results

Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacoth...
https://doi.org/10.1080/15360288.2022.2063469
Journal of Pain & Palliative Care Pharmacotherapy; Celichowska M, Miedziaszczyk M et. al.

Jun 28th, 2022 - Cachexia is a state of increased metabolism associated with high morbidity and mortality. Dysregulation of cytokines and hormone activity causes reduced protein synthesis and excessive protein breakdown. various treatments are available, depending...

Basal serum level of Δ4-androstenedione reflects the ovaries' ability to respond to sti...
https://doi.org/10.1007/s10815-022-02546-5 10.1093/humrep/der106 10.1093/humrep/den219 10.1016/j.fertnstert.2014.12.120 10.1093/humupd/dmm034 10.1016/S0015-0282(02)02972-2 10.1093/humupd/8.2.141 10.1016/j.fertnstert.2003.10.030 10.1016/j.fertnstert.2013.04.024 10.1093/humupd/dml034 10.1093/humupd/dmp036 10.1093/humupd/dmn001 10.1093/humrep/der092 10.1093/humrep/deg205 10.1095/biolreprod.106.051813 10.1095/biolreprod.107.064089 10.1210/me.2010-0006 10.1093/molehr/gaq073 10.1016/S0015-0282(02)02985-0 10.1016/j.fertnstert.2012.10.011 10.1097/gme.0b013e3180f6108c 10.1093/humrep/det033 10.1016/S0303-7207(02)00062-X 10.1210/jc.2003-030727 10.1038/nrendo.2013.212 10.1016/j.fertnstert.2003.11.032 10.1016/j.fertnstert.2005.12.028 10.1186/1477-7827-9-9 10.1007/s10815-014-0246-8 10.4300/JGME-D-12-00156.1 10.1016/j.fertnstert.2009.04.040 10.1093/humrep/det303 10.1186/s13048-017-0330-7 10.1016/j.mce.2017.04.024 10.1016/j.mce.2017.06.026 10.1530/jrf.0.1130027 10.1210/endo.142.11.8482 10.1186/s12958-016-0158-9 10.1093/humrep/15.10.2129 10.1093/humrep/del254 10.1186/1477-7827-9-67 10.1016/j.fertnstert.2007.11.055 10.1016/j.fertnstert.2011.04.083 10.1007/s10815-007-9178-x 10.1210/jc.2012-3071 10.1016/j.ejogrb.2017.09.006 10.3109/09513590.2014.964639
Journal of Assisted Reproduction and Genetics; Garzia E, Galiano V et. al.

Jun 28th, 2022 - Adequate androgen levels are necessary for regular follicular growth, progression beyond the pre-antral stage, and prevention of follicular atresia. The main purpose of this study was to investigate whether baseline androgen levels had a predictiv...

Associations of resting and peak fat oxidation with sex hormone profile and blood gluco...
https://doi.org/10.1016/j.numecd.2022.06.001
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Karppinen JE, Juppi HK et. al.

Jun 26th, 2022 - Menopause may reduce fat oxidation. We investigated whether sex hormone profile explains resting fat oxidation (RFO) or peak fat oxidation (PFO) during incremental cycling in middle-aged women. Secondarily, we studied associations of RFO and PFO w...

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02876107

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. To determine the pathologic complete response (pCR) rate in patients with primary triple-receptor negative (estrogen receptor [ER]-negative, progesterone receptor [PgR]-negative, and human epidermal growth factor receptor 2 ...

see more →

Guidelines  12 results

Diagnosis and treatment of luteal phase deficiency: a committee opinion.
https://doi.org/10.1016/j.fertnstert.2021.02.010
Fertility and Sterility;

Apr 9th, 2021 - Luteal phase deficiency (LPD) is a clinical diagnosis associated with an abnormal luteal phase length of ≤10 days. Potential etiologies of LPD include inadequate progesterone duration, inadequate progesterone levels, or endometrial progesterone re...

Guideline No. 398: Progesterone for Prevention of Spontaneous Preterm Birth.
https://doi.org/10.1016/j.jogc.2019.04.012
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Jain V, McDonald SD et. al.

Jun 1st, 2020 - To assess the benefits and risks of progesterone therapy for women at increased risk of spontaneous preterm birth (SPB) and to make recommendations for the use of progesterone to reduce the risk of SPB and improve postnatal outcomes. To administer...

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.
https://doi.org/10.1016/j.maturitas.2020.03.007
Maturitas Anagnostis P, Bitzer J et. al.

Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
https://doi.org/10.1200/JCO.19.02309
Journal of Clinical Oncology : Official Journal of the Am... Allison KH, Hammond MEH et. al.

Jan 14th, 2020 - To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. A multidisciplinary international Expert Panel was conven...

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY...
https://doi.org/10.4158/EP171828.PS
Endocrine Practice : Official Journal of the American Col... Cobin RH, Goodman NF et. al.

Jul 14th, 2017 - EXECUTIVE SUMMARY This American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) Position Statement is designed to update the previous menopause clinical practice guidelines published in 2011 but does not rep...

see more →

Drugs  249 results see all →

Clinicaltrials.gov  1,329 results

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02876107

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. To determine the pathologic complete response (pCR) rate in patients with primary triple-receptor negative (estrogen receptor [ER]-negative, progesterone receptor [PgR]-negative, and human epidermal growth factor receptor 2 ...

Endometrial Basis for Infertility in Women With Recurrent Implantation Failure and Pregnancy Loss
https://clinicaltrials.gov/ct2/show/NCT04939064

Jun 24th, 2022 - Pregnancy loss is the most common complication of human gestation, occurring in roughly one-half of natural conceptions and most frequently in the first two to three weeks of gestation. In recent years it has become apparent that constitutive endo...

IVF Treatment in Women With Immature Oocytes in Previous Cycle
https://clinicaltrials.gov/ct2/show/NCT02368964

Jun 24th, 2022 - Patients will be prospectively randomized into two groups. The randomization will be organized through the computer. The hCG group- will be triggered for final follicular maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration,...

The Role of Hormones in Postpartum Mood Disorders
https://clinicaltrials.gov/ct2/show/NCT00001481

Jun 24th, 2022 - The appearance of mood and behavioral symptoms during pregnancy and the postpartum period has been extensively reported. While there has been much speculation about possible biologically based etiologies for postpartum disorders (PPD), none has ev...

The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Randomized Trial
https://clinicaltrials.gov/ct2/show/NCT05050916

Jun 24th, 2022 - Study Description: This Phase II randomized, dose-ranging clinical trial translates both animal studies and human observational research into public health relevant research. We will investigate vitamin D s influence on the hypothalamic-pituitary-...

see more →

News  894 results

Metformin disappoints in high-risk operable breast cancer
https://www.mdedge.com/hematology-oncology/article/255687/breast-cancer/metformin-disappoints-high-risk-operable-breast

Jun 23rd, 2022 - Key clinical point: In patients with high-risk operable breast cancer (BC) and without diabetes, adding metformin to standard BC treatment did not improve the invasive disease-free survival (iDFS) rate, regardless of estrogen receptor/progesterone.

The Safest Option for Menopausal Hormone Therapy
https://www.medscape.com/viewarticle/975020

Jun 20th, 2022 - This transcript has been edited for clarity. In the four decades that I've been in practice, the main safety concern patients have expressed regarding menopausal hormone therapy (HT) is that it might increase risk for breast cancer. Given how comm...

Double morning-after pill dose for women with obesity not effective
https://www.mdedge.com/obgyn/article/255336/contraception/double-morning-after-pill-dose-women-obesity-not-effective
Marcia Frellick

Jun 9th, 2022 - Emergency contraception is more likely to fail in women with obesity, but simply doubling the dose of levonorgestrel (LNG)-based contraception does not appear to be effective according to the results of a randomized, controlled trial. Alison B.

Women with HER2+ metastatic breast cancer are living longer
https://www.mdedge.com/hematology-oncology/article/255238/asco-breast-cancer/women-her2-metastatic-breast-cancer-are-living
Walter Alexander

Jun 7th, 2022 - When a patient first presents to a doctor with signs and symptoms of having breast cancer that has metastasized to other parts of the body, the prospects of long-term survival are dim. But now, a new study presented at the annual meeting of the Am.

A Latinx Patient in Severe Pain
https://www.medscape.com/viewarticle/974437

May 26th, 2022 - To focus on issues of pain management in primary care, this month I'm presenting a clinical scenario involving a woman with acute pain. I'll tell you what I plan to do, but I'm most interested in crowdsourcing a response from all of you to collect...

see more →

Patient Education  21 results see all →